134 related articles for article (PubMed ID: 32057093)
21. Toll-like receptor 9 signaling in chronic lymphocytic leukemia cell lines.
Meloni M; Sana I; Mantione ME; Riba M; Muzio M
FEBS Open Bio; 2023 Dec; 13(12):2367-2374. PubMed ID: 37881888
[TBL] [Abstract][Full Text] [Related]
22. The expression of inhibitor of bruton's tyrosine kinase gene is progressively up regulated in the clinical course of chronic lymphocytic leukaemia conferring resistance to apoptosis.
Albano F; Chiurazzi F; Mimmi S; Vecchio E; Pastore A; Cimmino C; Frieri C; Iaccino E; Pisano A; Golino G; Fiume G; Mallardo M; Scala G; Quinto I
Cell Death Dis; 2018 Jan; 9(1):13. PubMed ID: 29317636
[TBL] [Abstract][Full Text] [Related]
23. The dual inhibitor of the phosphoinositol-3 and PIM kinases, IBL-202, is effective against chronic lymphocytic leukaemia cells under conditions that mimic the hypoxic tumour microenvironment.
Crassini K; Shen Y; O'Dwyer M; O'Neill M; Christopherson R; Mulligan S; Best OG
Br J Haematol; 2018 Sep; 182(5):654-669. PubMed ID: 29978459
[TBL] [Abstract][Full Text] [Related]
24. The vascular endothelial growth factor receptor tyrosine kinase inhibitors vatalanib and pazopanib potently induce apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo.
Paesler J; Gehrke I; Gandhirajan RK; Filipovich A; Hertweck M; Erdfelder F; Uhrmacher S; Poll-Wolbeck SJ; Hallek M; Kreuzer KA
Clin Cancer Res; 2010 Jul; 16(13):3390-8. PubMed ID: 20570929
[TBL] [Abstract][Full Text] [Related]
25. BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies.
Robak T; Robak P
Int Rev Immunol; 2013 Aug; 32(4):358-76. PubMed ID: 23617253
[TBL] [Abstract][Full Text] [Related]
26. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.
Wiestner A
Haematologica; 2015 Dec; 100(12):1495-507. PubMed ID: 26628631
[TBL] [Abstract][Full Text] [Related]
27. Characterization of the interleukin 1 receptor-associated kinase 4 (IRAK4)-encoding gene in salmonid fish: the functional copy is rearranged in Oncorhynchus mykiss and that factor can impair TLR signaling in mammalian cells.
Brietzke A; Goldammer T; Rebl H; Korytář T; Köllner B; Yang W; Rebl A; Seyfert HM
Fish Shellfish Immunol; 2014 Jan; 36(1):206-14. PubMed ID: 24239597
[TBL] [Abstract][Full Text] [Related]
28. Heterogeneous functional effects of concomitant B cell receptor and TLR stimulation in chronic lymphocytic leukemia with mutated versus unmutated Ig genes.
Chatzouli M; Ntoufa S; Papakonstantinou N; Chartomatsidou E; Anagnostopoulos A; Kollia P; Ghia P; Muzio M; Stamatopoulos K; Belessi C
J Immunol; 2014 May; 192(10):4518-24. PubMed ID: 24719462
[TBL] [Abstract][Full Text] [Related]
29. Total expression of HLA-G and TLR-9 in chronic lymphocytic leukemia patients.
Własiuk P; Tomczak W; Zając M; Dmoszyńska A; Giannopoulos K
Hum Immunol; 2013 Dec; 74(12):1592-7. PubMed ID: 23994589
[TBL] [Abstract][Full Text] [Related]
30. Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia.
Fiorcari S; Maffei R; Audrito V; Martinelli S; Ten Hacken E; Zucchini P; Grisendi G; Potenza L; Luppi M; Burger JA; Deaglio S; Marasca R
Oncotarget; 2016 Oct; 7(40):65968-65981. PubMed ID: 27602755
[TBL] [Abstract][Full Text] [Related]
31. Disrupting pro-survival and inflammatory pathways with dimethyl fumarate sensitizes chronic lymphocytic leukemia to cell death.
Mantione ME; Meloni M; Sana I; Bordini J; Del Nero M; Riba M; Ranghetti P; Perotta E; Ghia P; Scarfò L; Muzio M
Cell Death Dis; 2024 Mar; 15(3):224. PubMed ID: 38494482
[TBL] [Abstract][Full Text] [Related]
32. Cortactin, a Lyn substrate, is a checkpoint molecule at the intersection of BCR and CXCR4 signalling pathway in chronic lymphocytic leukaemia cells.
Martini V; Gattazzo C; Frezzato F; Trimarco V; Pizzi M; Chiodin G; Severin F; Scomazzon E; Guzzardo V; Saraggi D; Raggi F; Martinello L; Facco M; Visentin A; Piazza F; Brunati AM; Semenzato G; Trentin L
Br J Haematol; 2017 Jul; 178(1):81-93. PubMed ID: 28419476
[TBL] [Abstract][Full Text] [Related]
33. Autologous plasma activates Akt/protein kinase B and enhances basal survival and resistance to DNA damage-induced apoptosis in B-chronic lymphocytic leukaemia cells.
Wickremasinghe RG; Ganeshaguru K; Jones DT; Lindsay C; Spanswick VJ; Hartley JA; Wadhwa M; Thorpe R; Hoffbrand AV; Prentice HG; Mehta AB
Br J Haematol; 2001 Sep; 114(3):608-15. PubMed ID: 11552986
[TBL] [Abstract][Full Text] [Related]
34. BCR pathway inhibition as therapy for chronic lymphocytic leukemia and lymphoplasmacytic lymphoma.
Wiestner A
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):125-34. PubMed ID: 25696845
[TBL] [Abstract][Full Text] [Related]
35. Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib.
Yu J; Chen L; Cui B; Wu C; Choi MY; Chen Y; Zhang L; Rassenti LZ; Widhopf Ii GF; Kipps TJ
Leukemia; 2017 Jun; 31(6):1333-1339. PubMed ID: 27904138
[TBL] [Abstract][Full Text] [Related]
36. Emergence of Bruton's tyrosine kinase-negative Hodgkin lymphoma during ibrutinib treatment of chronic lymphocytic leukaemia.
Glavey S; Quinn J; McCloy M; Sargent J; McCartney Y; Catherwood M; Marafioti T; Leader M; Murphy P; Thornton P
Eur J Haematol; 2017 Oct; 99(4):378-380. PubMed ID: 28561533
[TBL] [Abstract][Full Text] [Related]
37. Ibrutinib induces rapid down-regulation of inflammatory markers and altered transcription of chronic lymphocytic leukaemia-related genes in blood and lymph nodes.
Palma M; Krstic A; Peña Perez L; Berglöf A; Meinke S; Wang Q; Blomberg KEM; Kamali-Moghaddam M; Shen Q; Jaremko G; Lundin J; De Paepe A; Höglund P; Kimby E; Österborg A; Månsson R; Smith CIE
Br J Haematol; 2018 Oct; 183(2):212-224. PubMed ID: 30125946
[TBL] [Abstract][Full Text] [Related]
38. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
Deng J; Isik E; Fernandes SM; Brown JR; Letai A; Davids MS
Leukemia; 2017 Oct; 31(10):2075-2084. PubMed ID: 28111464
[TBL] [Abstract][Full Text] [Related]
39. Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.
Cervantes-Gomez F; Lamothe B; Woyach JA; Wierda WG; Keating MJ; Balakrishnan K; Gandhi V
Clin Cancer Res; 2015 Aug; 21(16):3705-15. PubMed ID: 25829398
[TBL] [Abstract][Full Text] [Related]
40. Pro-survival signal inhibition by CDK inhibitor dinaciclib in Chronic Lymphocytic Leukaemia.
Chen Y; Germano S; Clements C; Samuel J; Shelmani G; Jayne S; Dyer MJ; Macip S
Br J Haematol; 2016 Nov; 175(4):641-651. PubMed ID: 27469405
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
